Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Impact of variable CYP genotypes on breast cancer relapse in patients undergoing adjuvant tamoxifen therapy.

Cancer chemotherapy and pharmacology - 1 Jun 2014

Mwinyi Jessica, Vokinger Kerstin, Jetter Alexander, Breitenstein Urs, Hiller Christian, Kullak-Ublick Gerd A, Trojan Andreas

Abstract excerpt

BACKGROUND: Tamoxifen is frequently used for the treatment of hormone receptor positive breast cancer (BC). Mainly CYP2D6 is responsible for the transformation to therapeutically active metabolites, but CYP2C19, CYP2C9 and CYP2B6 also are involved. We investigated the impact of polymorphisms within the genes encoding these CYP enzymes on the relapse-free time (RFT) in patients with BC. METHODS: Ninety-nine...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Breast Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Chemotherapy, Adjuvant

Share to Cytochrome P-450 CYP2D6

Share to Isoenzymes

Share to Neoplasm Recurrence, Local

Share to Polymorphism, Genetic

Share to Tamoxifen

Source

Identifiers

PMID: 24682508
DOI: 10.1007/s00280-014-2453-5

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Impact of variable CYP genotypes on breast cancer relapse in patients undergoing adjuvant tamoxifen therapy.PMID 24682508Read ↗

The frequencies of CYP2D6 alleles and their impact on clinical outcomes of adjuvant tamoxifen therapy in Syrian breast cancer patients.Semantic proximity Read ↗

Influence of CYP2D6 and CYP3A4 Phenotypes, Drug Interactions, and Vitamin D Status on Tamoxifen Biotransformation.Semantic proximity Read ↗

CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1-98 trial.Semantic proximity Read ↗

CYP2D6 as a treatment decision aid for ER-positive non-metastatic breast cancer patients: a systematic review with accompanying clinical practice guidelines.Semantic proximity Read ↗

Clinical Relevance of CYP2D6 Genetics for Tamoxifen Response in Breast CancerSemantic proximity Read ↗

Effect of CYP2C19 genotypes on tamoxifen metabolism and early-breast cancer relapse.Semantic proximity Read ↗

Effect of CYP2D6 polymorphisms on breast cancer recurrence.Semantic proximity Read ↗

CYP2D6 Genotype and Risk of Recurrence in Tamoxifen Treated Breast Cancer Patients.Semantic proximity Read ↗

CYP2D6 phenotype indicative for optimized antiestrogen efficacy associates with outcome in early breast cancer patients.Semantic proximity Read ↗

Effect of CYP2C19 and CYP2D6 genotype on tamoxifen treatment outcome indicates endogenous and exogenous interplay.Semantic proximity Read ↗

The impact of CYP2D6-predicted phenotype on tamoxifen treatment outcome in patients with metastatic breast cancer.Semantic proximity Read ↗

CYP2D6 polymorphisms influence tamoxifen treatment outcomes in breast cancer patients: a meta-analysis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.